Literature DB >> 24588550

The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes.

S Lane1, A R Levy, J Mukherjee, J Sambrook, H Tildesley.   

Abstract

OBJECTIVE: The objective of this study was to estimate utility values for hypothetical health states that describe differences in weight and quality of life associated with type 2 diabetes mellitus (DM) from Canadians with type 2 DM. The impact on utility values was examined separately for participants with a body mass index (BMI) of 18 to less than 25 kg/m(2) ('healthy'), 25 to less than 30 ('overweight'), and 30 or more ('obese').
METHODS: The health state descriptions were modified from a published diabetes utility study. Health states included a base-case type 2 DM health state (at participants' current weight), and six health states where the weight and attendant quality of life impact varied (base case ±3%, ±5%, and ±7% weight). Utilities were elicited using the time trade-off technique. Linear regression modeling was used to estimate the utility increment or decrement associated with a one unit difference in BMI.
RESULTS: Among 96 participants, the mean age was 55 years and 51% were men. The mean BMI was 32 kg/m(2) and 84% wanted to lose weight. The mean (SD) utility for the base-case state was 0.911 (0.013). Mean utilities (utility decrements) were 0.907 (-0.004), 0.865 (-0.046) and 0.806 (-0.105) for the health states describing an increased weight of 3%, 5% and 7%, respectively; and 0.923 (+0.012), 0.940 (+0.029) and 0.949 (+0.038) for the health states describing a decreased weight of 3%, 5% and 7%, respectively. For every increase of 1 kg/m(2) BMI there was an associated decrease in utility of 0.0472 (95% CI: 0.0375, 0.0569) and for every decrease of 1 kg/m(2) BMI there was an associated increase in utility of 0.0171 (95% CI: 0.0103, 0.0238).
CONCLUSIONS: The preferences of Canadian patients with type 2 DM for diabetes-related health states varied according to the weight, and quality of life impact, associated with that health state. Increased weight had a greater effect on utilities than decreased weight.

Entities:  

Keywords:  Quality of life; Time trade-off; Type 2 diabetes; Utility; Weight change

Mesh:

Year:  2014        PMID: 24588550     DOI: 10.1185/03007995.2014.899207

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  16 in total

1.  Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.

Authors:  Charalampos Tzanetakos; Alexandra Bargiota; Georgia Kourlaba; George Gourzoulidis; Nikos Maniadakis
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

2.  Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.

Authors:  Charalampos Tzanetakos; Nicholas Tentolouris; Georgia Kourlaba; Nikos Maniadakis
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

3.  Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK.

Authors:  Hayley Bennett; Phil McEwan; Klas Bergenheim; Jason Gordon
Journal:  Diabetes Ther       Date:  2014-09-04       Impact factor: 2.945

Review 4.  Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China.

Authors:  Shuyan Gu; Yuhang Zeng; Demin Yu; Xiaoqian Hu; Hengjin Dong
Journal:  PLoS One       Date:  2016-11-22       Impact factor: 3.240

5.  Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.

Authors:  Shuyan Gu; Yiming Mu; Suodi Zhai; Yuhang Zeng; Xuemei Zhen; Hengjin Dong
Journal:  PLoS One       Date:  2016-11-02       Impact factor: 3.240

6.  Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.

Authors:  Åsa Ericsson; Adam Lundqvist
Journal:  Appl Health Econ Health Policy       Date:  2017-04       Impact factor: 2.561

7.  A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer's Perspective.

Authors:  Mark Nuijten; Livia Dainelli; Bahareh Rasouli; Krysmaru Araujo Torres; Moreno Perugini; Agnieszka Marczewska
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-08       Impact factor: 3.168

8.  The Importance of Weight Change Experiences for Performance of Diabetes Self-Care: A Patient-Centered Approach to Evaluating Clinical Outcomes in Type 2 Diabetes.

Authors:  Shana B Traina; April Slee; Sangsoon Woo; William Canovatchel
Journal:  Diabetes Ther       Date:  2015-11-25       Impact factor: 2.945

9.  Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study.

Authors:  Martin Ridderstråle; Lyndon Marc Evans; Henrik Holm Jensen; Mette Bøgelund; Marie Markert Jensen; Åsa Ericsson; Johan Jendle
Journal:  Health Qual Life Outcomes       Date:  2016-01-22       Impact factor: 3.186

10.  Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.

Authors:  M Charokopou; P McEwan; S Lister; L Callan; K Bergenheim; K Tolley; R Postema; R Townsend; M Roudaut
Journal:  BMC Health Serv Res       Date:  2015-11-05       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.